• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta ophthalmologica Scandinavica >Longterm follow-up of diode laser transscleral cyclophotocoagulation in the treatment of refractory glaucoma
【24h】

Longterm follow-up of diode laser transscleral cyclophotocoagulation in the treatment of refractory glaucoma

机译：二极管激光经巩膜环光凝治疗难治性青光眼的长期随访

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: This prospective study was conducted to evaluate the efficacy and safety of transscleral diode laser cyclophotocoagulation (TDLCP) in advanced refractory glaucoma.Methods: A total of 124 eyes in 121 patients with advanced glaucoma refractory to medical treatment were treated consecutively with TDLCP. Success was defined as final intraocular pressure (IOP) of 5-21 mmHg in eyes with visual acuity (VA) of more than hand movements (HM) and relief of pain in eyes with VA of HM or less, including blind eyes.Results: Mean patient age was 65.6 +- 17.1 years (range 14-91 years). Mean follow-up was 17 +- 14.6 months (range 3-42 months). Mean pretreatment IOP was 29.9 +- 8.4 mmHg (range 17-58 mmHg) and IOP at last follow-up was 20.8 +- 8 mmHg (range 6-45 mmHg) (p < 0.001). The number of laser applications (mean 9.2 +- 2.8, range 4-15) and maximal laser power (mean 2.01 +- 0.22 mW, range 1.3-3.0 mW) were not associated with lower postoperative IOP. Intraocular pressure of < 21 mmHg was recorded in 63.0% of eyes at the last follow-up visit. Overall, 28 (21.7%) eyes required at least one retreatment. No phthisis bulbi or persistent hypotonia developed. Conclusions: TDLCP is an effective and safe method for the treatment of advanced refractory glaucoma, although repeated treatments are often necessary.
机译：目的：本前瞻性研究旨在评估经巩膜二极管激光循环光凝术（TDLCP）治疗晚期难治性青光眼的有效性和安全性。方法：对121例经药物治疗难治性晚期青光眼的124只眼进行连续治疗。成功的定义是视力（VA）大于手部动作（HM）的眼睛的最终眼压（IOP）为5-21 mmHg，且HM VA或以下的眼睛（包括盲眼）的疼痛缓解。平均患者年龄为65.6±17.1岁（范围14-91岁）。平均随访时间为17±14.6个月（范围3-42个月）。平均预处理IOP为29.9±8.4 mmHg（范围17-58 mmHg），最后一次随访的IOP为20.8±8 mmHg（范围6-45 mmHg）（p <0.001）。激光手术的次数（平均9.2±2.8，范围4-15）和最大激光功率（平均2.01±0.22 mW，范围1.3-3.0 mW）与较低的术后IOP无关。在最后一次随访中，眼中眼压<21 mmHg的占63.0％。总体而言，有28只（21.7％）眼睛需要至少一次重新治疗。没有发展成球状隆起或持续性肌张力低下。结论：TDLCP是治疗晚期难治性青光眼的一种有效且安全的方法，尽管经常需要反复治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号